Although President Obama has favored funding for embryonic stem cell research, the moral debate continues. But that discussion may overshadow the fact that biotech companies have actually made the most early progress, not in embryonic stem cells, but in adult stem cells. Dr. Robert Harman, chief executive officer and founder of Vet-Stem, joins the Chicago Tribune's Bruce Japsen. Vet-Stem is using stem-cell therapy in veterinary regenerative medicine that may one day benefit humans. In this interview, they discuss adult stem cells, and the major momentum in research and commercialized treatments.